引用次数
引用: 29,328
H-指数: 89
I10-指数 : 262
出版物: 760
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research (vol 47, pg 436, 2010)
RC Fitzgerald , R Hardwick , D Huntsman , NC Van Grieken
Journal of Medical Genetics 48 ( 3) 216 -216
1
2011
1491P bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
E Ococks , A Ng , G Devonshire , S Dashner
Annals of Oncology 31 S926 -S926
1
2020
The Mutational Landscape of Human Somatic and Germline Cells.
R Rahbari , L Moore , A Cagan , THH Coorens
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 62 51 -52
2021
Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus
William RC Knight , Ricardo McEwen , Ben E Byrne , Wais Habib
European Journal of Surgical Oncology 46 ( 12) 2257 -2261
3
2020
Germline genetic variants and risk of Barrett's esophagus and esophageal adenocarcinoma: a large scale meta-analysis of genome-wide association studies
CL Palles , I Tomlinson , L Chegwidden , P Gharahkhani
Lancet Oncology 17 ( 10)
2016
A non-endoscopic device to sample the oesophageal microbiota: a case-control study (vol 2, pg 32, 2017)
Fels DR Elliott , AW Walker , M O'Donovan , J Parkhill
LANCET GASTROENTEROLOGY & HEPATOLOGY 2 ( 11) E7 -E7
2017
Correction to Lancet Gastroenterol Hepatol
DR Fels Elliott , AW Walker , M O’Donovan , J Parkhill
Gastroenterol Hepatol 2 785 -92
2017
Use of a non-endoscopic device to sample the oesophageal microbiota: a case-control study (vol 2, pg 32, 2017)
Fels DR Elliott , AW Walker , M O'Donovan , J Parkhill
LANCET GASTROENTEROLOGY & HEPATOLOGY 2 ( 1) E1 -E1
2017
Correction to Lancet Gastroenterol Hepatol 2017; 2: 32–42
DR Fels Elliott , AW Walker , M O’Donovan , J Parkhill
Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy
EC Smyth , D Watson , MP Castro , B Nutzinger
ESMO Gastrointestinal Oncology 3 100010 -100010
2024
A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium
CJ Peters , Y Ang , FD Ciccarelli , H Coles
Nature Medicine 30 ( 1) 14 -16
2024
1572P Impact of HER2 and PD-L1 co-expression in Claudin18. 2 positive resectable gastroesophageal cancers
A Cammarota , G Devonshire , A Miremadi , A Ustaoglu
Annals of Oncology 34 S877 -S878
2023
Multi-omic cross-sectional cohort study of pre-malignant Barrett’s esophagus reveals early structural variation and retrotransposon activity
AC Katz-Summercorn , S Jammula , A Frangou , I Peneva
Nature Communications 13 ( 1) 1407 -1407
20
2022
Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis (vol 13, pg 77, 2015)
DA Katzka , DM Geno , A Ravi , TC Smyrk
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 13 ( 8) 1552 -1552
2015
Mini-chromosome maintenance proteins provide a novel method for detecting patients at risk of developing adenocarcinoma in Barrett's oesophagus
PS Sirieix , M O'Donovan , J Brown , N Coleman
GUT 52 A46 -A46
2003
Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants
RC Fitzgerald , BA Onwuegbusi , M Bajaj-Elliott , IT Saeed
Gut 50 ( 4) 451 -459
212
2002
Inflammatory gradient in Barrett’s oesophagus: implications for disease complications
RC Fitzgerald , S Abdalla , BA Onwuegbusi , P Sirieix
Gut 51 ( 3) 316 -322
150
2002
Clinical implications of E-cadherin associated hereditary diffuse gastric cancer
RC Fitzgerald , C Caldas
Gut 53 ( 6) 775 -778
78
2004
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
Fergus Noble , MA Lloyd , Richard Turkington , Ewen Griffiths
British Journal of Surgery 104 ( 13) 1816 -1828
41
2017
Barrett's oesophagus and associated adenocarcinoma–a UK perspective
RC Fitzgerald
Alimentary pharmacology & therapeutics 20 45 -49
33
2004